Upgrade to SI Premium - Free Trial

Gilead Sciences (GILD)

66.95 +0.19 (0.28%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (4/25/24)
- M&A (6/30/20 *Est)
- M&A (12/31/20 *Est)

Latest Headlines

Gilead Sciences (GILD) PT Lowered to $75 at UBS April 17, 2024 8:14 AM - StreetInsider Truist Securities Assumes Gilead Sciences (GILD) at Hold April 15, 2024 4:48 PM - StreetInsider Gilead Sciences (GILD) PT Lowered to $80 at Morgan Stanley April 9, 2024 9:40 AM - StreetInsider Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024 April 8, 2024 4:05 PM - BizWire Form 4 GILEAD SCIENCES, INC. For: Apr 01 Filed by: Parsey Merdad April 2, 2024 6:39 PM - SEC Filing Nurix Therapeutics (NRIX) Announces Extension of Collaboration with Gilead Sciences (GILD) April 2, 2024 7:06 AM - StreetInsider Form 144 GILEAD SCIENCES, INC. Filed by: Parsey Merdad April 1, 2024 4:55 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Mar 28 Filed by: Lofton Kevin E March 29, 2024 5:20 PM - SEC Filing Form ARS GILEAD SCIENCES, INC. For: Dec 31 March 28, 2024 4:24 PM - SEC Filing Form DEF 14A GILEAD SCIENCES, INC. For: May 08 March 28, 2024 4:14 PM - SEC Filing Form DEFA14A GILEAD SCIENCES, INC. March 28, 2024 4:10 PM - SEC Filing FDA Expands Indication for Gilead's (GILD) Vemlidy to Treat Chronic HBV Infection in Pediatric Patients as Young as Six March 28, 2024 8:31 AM - StreetInsider FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six March 28, 2024 8:30 AM - BizWire Xilio Therapeutics (XLO) Announces $11.3 Million Private Placement Equity Financing, License Agreement with Gilead (GILD) March 28, 2024 7:05 AM - StreetInsider Gilead Sciences (GILD) and Xilio (XLO) Enter Exclusive License Agreement for Tumor-Activated IL-12 Program March 28, 2024 7:02 AM - StreetInsider Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program March 28, 2024 7:00 AM - StreetInsider Gilead (GILD) reduces 2024 earnings guidance after completing CymaBay takeover March 22, 2024 9:56 AM - StreetInsider Form 8-K GILEAD SCIENCES, INC. For: Mar 22 March 22, 2024 9:21 AM - SEC Filing Gilead Sciences (GILD) Announces Completion of Acquisition of CymaBay (CBAY) March 22, 2024 9:18 AM - StreetInsider Gilead Sciences Announces Completion of Acquisition of CymaBay March 22, 2024 9:18 AM - BizWire Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant March 18, 2024 7:29 PM - BizWire Form PRE 14A GILEAD SCIENCES, INC. For: May 08 March 18, 2024 4:08 PM - SEC Filing BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD) March 15, 2024 10:25 AM - StreetInsider Gilead Sciences (GILD) Board Member Kevin Lofton to Retire March 14, 2024 4:09 PM - StreetInsider Form 8-K GILEAD SCIENCES, INC. For: Mar 10 March 14, 2024 4:06 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Telman Deborah H March 12, 2024 4:19 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Patterson Sandra March 12, 2024 3:58 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Parsey Merdad March 11, 2024 9:15 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: O'Day Daniel Patrick March 11, 2024 9:12 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Mercier Johanna March 11, 2024 9:03 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Dickinson Andrew D March 11, 2024 9:00 PM - SEC Filing Gilead Sciences (GILD) Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay (CBAY) Tender Offer March 11, 2024 8:24 AM - StreetInsider Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer March 11, 2024 8:24 AM - BizWire Oppenheimer remain bullish on Gilead Sciences (GILD), HIV agents in 24/25 could provide conviction to investors March 8, 2024 1:21 PM - StreetInsider Gilead Sciences (GILD) and Merck (MRK) Report Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 March 6, 2024 10:25 AM - StreetInsider Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 March 6, 2024 10:25 AM - BizWire Gilead Sciences (GILD), Merus (MRUS) Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers March 6, 2024 8:01 AM - StreetInsider Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers March 6, 2024 8:00 AM - BizWire Gilead Sciences (GILD) Reports New Real-World Data Supporting the Use of Veklury for People Hospitalized With COVID-19 March 5, 2024 4:35 PM - StreetInsider New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19 March 5, 2024 4:35 PM - BizWire Gilead Sciences (GILD) HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health March 5, 2024 4:31 PM - StreetInsider Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health March 5, 2024 4:30 PM - BizWire RedHill Biopharma's (RDHL) Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs March 5, 2024 7:03 AM - StreetInsider RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs March 5, 2024 7:00 AM - PR NewsWire Gilead Sciences (GILD) PT Lowered to $78 at Wells Fargo March 4, 2024 4:54 AM - StreetInsider Form 4 GILEAD SCIENCES, INC. For: Feb 28 Filed by: Parsey Merdad February 29, 2024 6:36 PM - SEC Filing Form 144 GILEAD SCIENCES, INC. Filed by: Parsey Merdad February 29, 2024 4:52 PM - SEC Filing Gilead Announces Funding Initiative To Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S. February 28, 2024 5:17 PM - StreetInsider Form 144 GILEAD SCIENCES, INC. Filed by: Parsey Merdad February 28, 2024 4:45 PM - SEC Filing Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S. February 27, 2024 10:00 AM - BizWire Gilead Sciences (GILD) Announces FDA Approval of Expanded Indication for Biktarvy February 26, 2024 4:07 PM - StreetInsider U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance February 26, 2024 4:05 PM - BizWire Gilead Sciences (GILD) to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024 February 26, 2024 8:33 AM - StreetInsider Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024 February 26, 2024 8:30 AM - BizWire Form 10-K GILEAD SCIENCES, INC. For: Dec 31 February 23, 2024 5:00 PM - SEC Filing Gilead Sciences (GILD) PT Lowered to $90 at Mizuho Securities February 22, 2024 6:48 AM - StreetInsider Truist Securities Downgrades Gilead Sciences (GILD) to Hold February 22, 2024 6:04 AM - StreetInsider Gilead Sciences to Present at Upcoming Investor Conferences February 20, 2024 4:05 PM - BizWire Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC February 20, 2024 9:27 AM - StreetInsider Gilead Sciences (GILD) and Biocytogen Enter Multi-Target Antibody Collaboration Agreement February 20, 2024 9:05 AM - StreetInsider RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication February 20, 2024 7:01 AM - PR NewsWire Gilead Sciences (GILD) PT Lowered to $75 at RBC Capital February 14, 2024 5:24 AM - StreetInsider Form SC 13G/A GILEAD SCIENCES, INC. Filed by: VANGUARD GROUP INC February 13, 2024 6:10 PM - SEC Filing Midday movers: Diamondback Energy rises, Arm goes parabolic February 12, 2024 9:00 AM - StreetInsider Gilead Sciences (GILD) to acquire CymaBay Therapeutics (CBAY) in $4.3bn cash deal February 12, 2024 8:55 AM - StreetInsider Gilead to buy CymaBay for $4.3 billion in bets on liver disease treatment February 12, 2024 8:42 AM - StreetInsider Form 8-K GILEAD SCIENCES, INC. For: Feb 11 February 12, 2024 8:38 AM - SEC Filing Gilead Sciences (GILD) to Acquire CymaBay Therapeutics (CBAY) for $32.50 Per Share, $4.3 Billion February 12, 2024 8:31 AM - StreetInsider Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics February 12, 2024 8:30 AM - BizWire Gilead Sciences (GILD) PT Lowered to $105 at Oppenheimer, 'continue to be bullish on the name' despite weaker Q4 sales February 12, 2024 6:32 AM - StreetInsider Gilead Sciences (GILD) PT Lowered to $80 at Barclays February 12, 2024 3:00 AM - StreetInsider Form SC 13G/A GILEAD SCIENCES, INC. Filed by: Capital World Investors February 9, 2024 6:22 PM - SEC Filing Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC February 9, 2024 11:00 AM - BizWire Gilead Sciences (GILD) PT Lowered to $83 at Morgan Stanley February 8, 2024 8:17 AM - StreetInsider Gilead Sciences (GILD) PT Raised to $81 at UBS February 8, 2024 5:54 AM - StreetInsider Gilead Sciences (GILD) PT Lowered to $80 at DZ Bank February 8, 2024 4:23 AM - StreetInsider Gilead Sciences (GILD) PT Lowered to $90 at TD Cowen February 7, 2024 9:01 AM - StreetInsider Gilead Sciences (GILD) PT Lowered to $95 at Piper Sandler February 7, 2024 8:25 AM - StreetInsider Gilead Sciences (GILD) PT Lowered to $84 at Wells Fargo February 7, 2024 7:12 AM - StreetInsider Gilead Sciences (GILD) PT Lowered to $76 at RBC Capital February 7, 2024 7:07 AM - StreetInsider Gilead Sciences Q4 earnings fall short of estimates February 7, 2024 5:57 AM - StreetInsider Form 4 GILEAD SCIENCES, INC. For: Feb 02 Filed by: LOVE TED W February 6, 2024 6:02 PM - SEC Filing After-hours movers: Snap sinks, Ford surges, and more February 6, 2024 5:01 PM - StreetInsider Form 3 GILEAD SCIENCES, INC. For: Feb 01 Filed by: LOVE TED W February 6, 2024 4:16 PM - SEC Filing Gilead Sciences (GILD) Declares $0.77 Quarterly Dividend; 4% Yield February 6, 2024 4:07 PM - StreetInsider Gilead quarterly revenue drops 4%, oral COVID drug fails trial February 6, 2024 4:06 PM - StreetInsider Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend February 6, 2024 4:05 PM - BizWire Form 8-K GILEAD SCIENCES, INC. For: Feb 06 February 6, 2024 4:04 PM - SEC Filing Gilead Sciences (GILD) Misses Q4 EPS by 4c; offers guidance February 6, 2024 4:04 PM - StreetInsider Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results February 6, 2024 4:02 PM - BizWire Eli Lilly earnings ahead, Toyota lifts annual guidance - what's moving markets February 6, 2024 5:40 AM - StreetInsider Form 8-K GILEAD SCIENCES, INC. For: Feb 01 February 2, 2024 4:21 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Jan 31 Filed by: Parsey Merdad February 2, 2024 2:42 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Jan 31 Filed by: Mercier Johanna February 2, 2024 2:35 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Jan 31 Filed by: Telman Deborah H February 2, 2024 2:19 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Jan 31 Filed by: Dickinson Andrew D February 2, 2024 2:12 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Jan 31 Filed by: O'Day Daniel Patrick February 2, 2024 1:40 PM - SEC Filing Gilead Sciences (GILD) Appoints Ted Love to its Board February 1, 2024 4:31 PM - StreetInsider Ted Love, MD, Joins Gilead Sciences’ Board of Directors February 1, 2024 4:31 PM - BizWire Gilead Sciences (GILD) Reports Kite Granted FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta January 30, 2024 8:31 AM - StreetInsider Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy January 30, 2024 8:30 AM - BizWire After-hours movers: Supermicro, F5 Networks and more January 29, 2024 5:04 PM - StreetInsider Gilead Sciences (GILD), Arcus (RCUS) Announce Amended Collaboration and $320M Equity Investment January 29, 2024 5:01 PM - StreetInsider Gilead and Arcus Announce Amended Collaboration and Equity Investment January 29, 2024 5:00 PM - BizWire Form 4 GILEAD SCIENCES, INC. For: Jan 25 Filed by: Telman Deborah H January 26, 2024 4:32 PM - SEC Filing Form SC 13G/A GILEAD SCIENCES, INC. Filed by: BlackRock Inc. January 24, 2024 2:28 PM - SEC Filing Full Article List